leisure time -WSS

leisure time

author：entertainment 2025-10-01 06:01:35 - browse：2

Person wearing a smart watch. -- first opinion coverage from STAT — Adobe

The Apple Watch has secured a new qualification from the Food and Drug Administration that could make the smartwatch an appealing tool for medical device companies hoping to illustrate the benefits of a common heart procedure.

Last week, the Apple Watch’s Atrial Fibrillation History feature became the first digital tool qualified under the Medical Device Development Tools (MDDT) program. Released in 2022, the feature estimates a user’s A-fib burden, or how much time they spend in atrial fibrillation, which is an irregular heart rhythm that can cause shortness of breath and fatigue, and is also linked to an increased risk of stroke.

The qualification means that FDA has determined in advance that sponsors can use the feature as a secondary endpoint in clinical trials without having to do additional work. Specifically, the Apple Watch is qualified for use as a secondary endpoint in clinical trials for cardiac ablation devices, which reduce the electrical signals that cause A-fib by scarring the heart with extreme heat or cold energy. Pulsed field ablation is the latest version of the technology, using a controlled electric field to scar tissue rather than the riskier thermal energy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Readout Newsletter: Merck, Vertex, and Viking updates

explore

WSS

The inclusion problem at the heart of rehabilitation research

Maisha Meds is a PBM, but don't call it that

Update the Apgar Score to remove skin color

To bolster infectious disease surveillance, genomics powerhouses team up

FDA's naming rule on biosimilars has undermined competition

Readout LOUD podcast: mifepristone case, GLP

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

Trump demands the U.S. pay no more for drugs than other countries … again

Abortion pill Supreme Court ruling could impact entire drug industry

23andMe had bad news about my health. I wish a person had delivered it

Decaf coffee targeted by food safety group under obscure FDA rule

Drug repurposing or repositioning? The language matters

Merck drug for rare lung condition set for approval in U.S.

Medicare details structure of new drug price negotiation program

Microsoft launches AI tool for clinical documentation through Epic

Continuity nursing helped my family in our darkest PICU moments

Flu vaccine reformulation won't be easy, manufacturers warn

hotspot

Dog Aging Project founders on what lies ahead after losing funding

There's no autism epidemic. It's an autism diagnosis epidemic

Microsoft launches AI tool for clinical documentation through Epic

Steward Health Care has deal to sell doctor network to UnitedHealth

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

FDA's naming rule on biosimilars has undermined competition

focus

explore

focus

Wikipedia